NCT02113033CompletedPhase 2
VAgal Nerve Stimulation: safeGUARDing Heart Failure Patients
Conditions
Interventions
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- LivaNova
- Enrollment
- 15
- Locations
- 12
- Primary Endpoint
- The primary outcome measure is the freedom from Serious Adverse Device Effects, defined as the number of patients without SADEs.
Study Overview
Brief Summary
The purpose of the VANGUARD study is to demonstrate the safety of Vagal Nerve Stimulation for the treatment of congestive heart failure with reduced ejection fraction, and to report secondary measures of efficacy.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Left ventricular dysfunction of ischemic or idiopathic dilated cardiomyopathy etiology, characterized by LVEF < 40%
- •Chronic heart failure with symptoms characterized by NYHA functional class II or III at the time of enrollment despite optimal drug regimen
- •Optimal drug regimen as defined in the current European guidelines
- •Sinus rhythm, with spontaneous heart rate ≥ 60bpm at the time of enrollment
- •Signed and dated informed consent
Exclusion Criteria
- •Patient implanted with or eligible to cardiac pacing as per current guideline
- •Risk for neck surgery in the electrode zone within a year after enrollment
- •Patient with right carotid artery stenosis
- •Symptomatic hypotension
- •History of peptic ulcer disease or upper gastrointestinal bleeding
- •Asthma, severe COPD, or severe restrictive lung disease
- •Advanced Diabetes Mellitus
- •Recent acute myocardial infarction, coronary artery surgery or revascularization (or already planned)
- •Recent cerebro-vascular event
- •Significant valvulopathy
- •Advanced Renal failure
- •Previous heart transplant or current LVAD device therapy
- •Life expectancy < 1 year for non-cardiac cause
- •Patient included in another clinical study that could confound the results of this study
- •Inability to understand the purpose of the study or to perform the procedures of the study
- •Unavailability for scheduled follow-up
- •Age of less than 18 years or under guardianship
- •Pregnancy
Arms & Interventions
Treated with Equilia system
Experimental
Implantation and activation of the Vagus Nerve Stimulator, nerve electrode and cardiac lead
Intervention: Equilia® Vagal Nerve Stimulation (Device)
Outcomes
Primary Outcomes
The primary outcome measure is the freedom from Serious Adverse Device Effects, defined as the number of patients without SADEs.
Time Frame: 6 Months
Adverse device effects will be sub-classified into device-related or procedure-related, when the adverse event has a generic cause independent from the device itself and occurs within 30 days of the implant procedure.
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (12)
Loading locations...
Similar Trials
Completed
Not Applicable
A Study to Evaluate the Effect of Vagus Nerve Stimulation in Patients Undergoing VT AblationVentricular Tachycardia (VT)ArrhythmiaNCT04359004University of California, Los Angeles5
Completed
Not Applicable
Safety and Feasibility of Paired Vagus Nerve Stimulation With Rehabilitation for Improving Upper Extremity Function in People With Cervical Spinal Cord InjuryCervical Spinal Cord InjuryNCT05601661The University of Texas Health Science Center, Houston6
Completed
Not Applicable
Relief of Acute Bronchoconstriction/Asthma Using the Non-Invasive AlphaCore DeviceAsthmaNCT01532817ElectroCore INC30
Completed
Not Applicable
Use of taVNS for Painful Diabetic Neuropathy: 12-Week Randomized, Sham-Controlled TrialDiabetic NeuropathiesDiabetes MellitusType2diabetesNeuropathic PainNCT06292962Saima Abass Tahammal185
Terminated
Not Applicable
Non-invasive Neurostimulation for the Relief of MigraineMigraineNCT03410628ElectroCore INC21